Article
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
PloS one - 1 Jan 2018
Hsieh Yi-Chung, Jeng Wen-Juei, Huang Chien-Hao, Teng Wei, Chen Wei-Ting, Chen Yi-Cheng, Lin Shi-Ming, Tai Dar-In, Lin Chun-Yen, Sheen I-Shyan
Abstract excerpt
BACKGROUND AND AIM: Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD). Till now, few papers regarding on-treatment hepatic decompensation have been reported. The study aims to analyze the general feature and predictive factors of on-treatment hepatic decompensation in hepatitis C virus (HCV) genotype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.